A New Route to Pharma GDP Compliance and Standardization

Published on: 
,
BioPharm International, BioPharm International, Regulatory Sourcebook March 2022, Volume 2022 eBook, Issue 1
Pages: 24-29

A consensus-based approach to GDP lies at the heart of a new industry-wide program seeking to rationalize, standardize, and harmonize the adherence to pharma transportation norms and regulatory guidelines.

The logistics associated with the safe and efficient physical transportation of pharmaceuticals is increasingly taxing the minds of logisticians as medicines become more complex and labile and their regulatory oversight intensifies. The statutory need to maintain the therapeutic and physical integrity of drugs during transit renders the management of quality and the adherence to good distribution practice (GDP) guidelines an absolutely critical part of the pharmaceutical supply process.

Read this article in Pharmaceutical Technology’s March 2022 Quality and Regulatory Sourcebook eBook.

About the author

Courtney Soulsby is sector director, Healthcare & Life Sciences, BSI.

Advertisement

Alan Kennedy is director, Team Poseidon.

Article Details

BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 24–29

Citation

When referring to this article, please cite it as C. Soulsby, A. Kennedy, “A New Route to Pharma GDP Compliance and Standardization," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).

Related Content:

Quality/GMPsRegulatory/GMP ComplianceQuality Control/Quality AssurancePackaging, Labeling, and Distribution SystemsBioPharm International, Regulatory Sourcebook March 2022
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials
FDA Eyes Advisory Committee Reform to Enhance Credibility
FDA Approves Topical Gene Therapy for Treating Wounds Associated with Rare Genetic Skin Disorder